Journals / Atatürk Üniversitesi Tıp Dergisi (Y. A. The Eurasian Journal of Medicine) / 1999 / Cilt: 31 - Sayı: 2

Serum haptoglobin level in patients with Hodgkin s disease and non-Hodgkin s lymphoma

Hodgkin hastalığı ve Hodgkin dışı lenfoma hastalarında serum haptoglobin seviyesi

Pages
53–56
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, it is possible to conclude that the evaluation of serum haptoglobin in malignant lymphomas patients could represent an additional and useful parameter in defining the clinical and prognostic aspects of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Serum levels of haptoglobin, lactic dehydrogenase (LDH) and ferritin are investigated in 68 patients with malignant lymphomas.
📊
Key Findings & Data:The study included 16 patients with stage IIIB Hodgkin's diseases (HD), 32 patients with stage IIIB non-Hodgkin's lymphomas (NHL), 10 patients with complete remission Hodgkin's diseases (R-HD), 10 patients with complete remission non-Hodgkin's lymphomas (R-NHL), and 20 normal people as control group.
💡
Conclusion & Impact:In this study, it is possible to conclude that the evaluation of serum haptoglobin in malignant lymphomas patients could represent an additional and useful parameter in defining the clinical and prognostic aspects of the disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Serum levels of haptoglobin, lactic dehydrogenase (LDH) and ferritin are investigated in 68 patients with malignant lymphomas. The study included 16 patients with stage IIIB Hodgkin's diseases (HD), 32 patients with stage IIIB non-Hodgkin's lymphomas (NHL), 10 patients with complete remission Hodgkin's diseases (R-HD), 10 patients with complete remission non-Hodgkin's lymphomas (R-NHL), and 20 normal people as control group. The upper limit of "normal" in our institution has been 200 mg/dl of haptoglobin, 460 U/L of LDH and 322 ng/ml of ferritin. Serum haptoglobin level was elevated in 75% of stage IIIB HD patients, in 78,1% of stage IIIB NHL patients. Serum LDH level was elevated in 81,2 % of stage IIIB HD patients, in 84,3% of stage IIIB NHL patients-Serum ferritin level was elevated in 62,5% of stage IIIB HD patients, in 59,3 % of stage IIIB NHL patients. Serum levels of haptoglobin, LDH and ferritin were normal in R-HD patients, in R-NHL patients ,and in control groups. In this study, it is possible to conclude that the evaluation of serum haptoglobin in malignant lymphomas patients could represent an additional and useful parameter in defining the clinical and prognostic aspects of the disease.

Özet

Bu çalışmada serum haptoglobinin malign lenfomalarda prognostik değeri araştırıldı, Çalışmaya 26 Hodgkin hastalığı (HD) ve 42 Hodgkin dışı lenfoma olmak üzere malign lenfomalı 68 hasta ve kontrol grubu olarak 20 sağlıklı kişi alındı. Ann Arbor sınıflandırmasına göre hastaların 48 (16 HD, 32 HDL)'i evre IIIB' de, 20 (10 HD, 10 HDL)'si remisyonda idi. Bulunan sonuçlar serum laktik dehidrogenaz (LDH) ve ferritin seviyesi ile karşılaştırıldı, Cut off değeri haptoglobin için 200 mg/dl, LDH için 460 U/L ve ferritin için 322 ng/ml olarak kabul edildi. Evre IIIB HD grubunda serum haptoglobin seviyesi 12 (%75), serum LDH seviyesi 13 (%81,2), serum ferritin seviyesi 10 (%62,5) hastada; evre IIIB HDL grubunda serum haptoglobin seviyesi 25 (%78,1), serum LDH seviyesi 27 (%84,3), serum ferritin seviyesi 19 (%59,3) hastada cut off değerinin üstünde idi. Remisyondaki HD, HDL ve kontrol gruplarındaki kişilerin hepsinde serum haptoglobin, LDH ve ferritin seviyeleri cut off değerinin altındaydı. Bu çalışma sonucunda, serum LDH ve ferritin seviyesi gibi, serum haptoglobin seviyesinin de, malign lenfomaların takip ve tedavisinde bir prognoz kriteri olarak kullanılabileceği düşünüldü.

🔖

Cite This Article

KAYA, H., GÜNDOĞDU, M., KİKİ, İ., AKARSU, E., TEKİN, S. B. (2022). Serum haptoglobin level in patients with Hodgkin s disease and non-Hodgkin s lymphoma. Atatürk Üniversitesi Tıp Dergisi (Y. A. The Eurasian Journal of Medicine), Cilt: 31 - Sayı: 2, 53–56. https://ajindex.com/articles/648793

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Esteve J, Lopez-Guillermo A, Martinez-Frances A, et al. Presenting features, natural history, and prognostic factors in localized non-Hodgkin's lymphomas: analysis of 117 cases from a single institution. Eur J Haematol 1995; 55: 217-222 2. Coiffier B. Prognostic factors in non-Hodgkin's lymphomas. Therapeutic implications. Rev Prat 1993; 43: 1640-1643 3. Garcia R, Hernandez JM, Caallero MD, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin' disease. Br J Cancer 1993; 68: 1227-1231 4. Aulbert E, Steffens 0. Serum ferritin- a tumor marker in malignant lymphomas? Onkologie 1990; 13: 102-108 5. Walesquez WS, Jagannath S, Tucker SI, et al. Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data. Blood 1989; 2: 551-557 6. Haznedar R. Primer Irombositemi. ilicin G, et al. (eds). Temel lc Hastaliklari. Ankara: Dine§ Kitabevi, 1996: 1277-1278 7. Henjr JB. Interpreting laboratory results: reference values and decision making. In: Winkel P (ed). Clinical Diagnosis Managament by Laboratory Methods. 18th ed., Philadelphia: 12. Lumley MA, Milligan DW, Knechtli CJ, et al. High lactate WB Saunders Company, 1991: 48-67 dehydrogenase level is associated with an adverse outlook in 8. Suki S, Swan F Jr, Tucker S, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and tymidine kinase. Leuk Lymphoma 1995; 18: 87-92 9. Cooper EH, Turner R, Geekie A, et al. Alpha-globulins in the surveillance of colorectal cancer. Biomedicine 1976; 24: 171- 178 10. Desai SS, Ishward CS, Balakrishnan V, et al. Serum haptoglobin level in patients with malignant lymphoma and its clinical significance. Indian J Cancer 1990; 27: 46-54 11. Shipp MA. Apredictive model for aggressive lymphoma: The International NHL Prognostic Factors Project. N. Engl J Med 1993; 329: 987-994 12. autografting for Hodgkin's disease. Bone Marrow Transplant 1996; 17: 383-388 13. Ferraris AM, Giuntini P, Gaetani F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin's lymphomas. Blood 1979; 54: 928-932